03
Oct
Panel: The continued importance of cross-border dealmaking for Switzerland
Swiss M&A is dominated by cross-border dealmaking – international players, both private equity and trade buyers, are targeting the important midmarket in their quest for alpha, while large Swiss multinationals continue to be key participants in global M&A. This session will explore the challenges and intricacies of cross-border deal making:
- What is the importance of cross-border dealmaking to Swiss M&A and the Swiss economy overall?
- Exploring Switzerland as an investment destination, how does the Swiss market view foreign buyers and what makes Switzerland an attractive destination?
- How are dealmakers using technology to enhance the deal process and navigate cultural differences?
-
SpeakersBrice Bolinger Head of M&A Switzerland UBS
Malte Jantz Member of the Executive Board, Partner Helbling Business Advisors
Reto Bärtschi Director, New Business Development and M&A Bruker BioSpin
Aurelia Seidlhofer Senior Correspondent DACH Mergermarket
Loading feed
Confirm cancellation
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.
CloseSign-up to join the ION Analytics Community to:
- Register for events
- Access market insights
- Download reports
Brice Bolinger is a Managing Director of UBS and Head of M&A Switzerland, based in Zurich. He joined Credit Suisse (now part of UBS) in 2008 from Novartis, where he worked in the Corporate M&A team. Brice started his career at UBS in 2004 in the Swiss Investment Banking team. Brice has been involved in some of the largest Swiss M&A transactions and has broad experience ranging from public M&A deals to complex carve-out transactions. He graduated from the Swiss Federal Institute of Technology (ETH Zurich) with a M.Sc. in industrial engineering and business administration with highest distinction. Brice is a CFA charterholder.
Professional background
Helbling Business Advisors AG, Zurich
Kaffenberger AG, Appenzell, Switzerland – Senior Manager, Chemical
Mergers & Acquisitions
DeStaCo Metallerzeugnisse GmbH, Oberursel, Germany
Hologenix Inc., Huntington Beach, USA
Industry focus
Specialty Chemicals
Engineering
Plastics & Packaging
Construction & Subconstruction Work
Textiles
Transportation & Logistics
Energy
Software & IT
Focus of competence
Mergers & Acquisitions
Turnaround Management
Corporate Finance
Succession Planning
Financial and Business Planning
Valuation
Reto Bärtschi is Director New Business Development and M&A at Bruker BioSpin. Bruker is a provider of high-value life science research and diagnostics solutions which enable scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.
Over the past 4 years, Reto has been responsible to drive the M&A process for a range of acquisitions globally, utilizing different M&A approaches that include strategic minority investments, “String-of-Pearls” acquisitions as well as “bolt-on” acquisitions.
Before joining Bruker, Reto was part of KPMG's Global Strategy Group for 5 years, supporting predominantly Life Science clients in developing and executing M&A strategies. Prior to joining KPMG, Reto supported the creation of a new business segment within Siemens for 5 years, which included also the acquisition and integration of companies adding to the solution portfolio.
Reto holds a master in Corporate Finance from the University of Zurich and has completed the INSEAD M&A and Corporate Strategy Program.
Aurelia Seidlhofer is a Senior Correspondent for the DACH region at Mergermarket. She joined in June and covers M&A, Private Equity and ECM markets. Aurelia has more than a decade of experience in financial journalism having covered commodities, restructuring & distressed debt as well as equity markets. Prior to joining Mergermarket she was the Deputy Editor of Restructuring & Distressed Debt at Reorg in London. She is based in Munich.